Effect of evolocumab on the gut microbiota in patients with acute myocardial infarction.

ABSTRACT: Introduction. Growing evidence indicates significant interactions between the intestinal microflora and drugs commonly used to treat coronary heart disease.Hypothesis/Gap Statement. Despite this, research specifically investigating the relationship between proprotein convertase subtilisin/kexin type 9 inhibitors and alterations in the gut microbiota has not been previously published.Aim. This study aimed to identify changes in the gut microbiota potentially associated with evolocumab use in patients with acute myocardial infarction (AMI).Methodology. In this prospective study, 26 AMI patients receiving statins (≥8 weeks) were administered evolocumab (420 mg/4 weeks) alongside standard therapy. Eighteen age-matched healthy volunteers served as controls. 16S rRNA

SUBMITTER: Zou J 

PROVIDER: S-EPMC12799316 | biostudies-literature | 2026 Jan

REPOSITORIES: biostudies-literature